-DOCSTART- -X- O
Degenerative -X- _ O
retinal -X- _ O
disease -X- _ O
leads -X- _ O
to -X- _ O
significant -X- _ O
visual -X- _ O
morbidity -X- _ O
worldwide. -X- _ O
Diabetic -X- _ B-Patient
retinopathy -X- _ I-Patient
and -X- _ I-Patient
macular -X- _ I-Patient
degeneration -X- _ I-Patient
are -X- _ O
leading -X- _ O
causes -X- _ O
of -X- _ O
blindness -X- _ O
in -X- _ O
the -X- _ O
developed -X- _ O
world. -X- _ O
While -X- _ O
current -X- _ O
therapies -X- _ O
for -X- _ O
these -X- _ O
diseases -X- _ O
slow -X- _ O
disease -X- _ O
progression -X- _ O
, -X- _ O
stem -X- _ B-Intervention
cell -X- _ I-Intervention
and -X- _ I-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
may -X- _ O
also -X- _ O
reverse -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
these -X- _ O
, -X- _ O
and -X- _ O
other -X- _ O
, -X- _ O
degenerative -X- _ O
retinal -X- _ O
conditions. -X- _ O
Novel -X- _ O
therapies -X- _ O
being -X- _ O
investigated -X- _ O
include -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
various -X- _ O
types -X- _ O
of -X- _ O
stem -X- _ O
cells -X- _ O
in -X- _ O
the -X- _ O
regeneration -X- _ B-Outcome
of -X- _ I-Outcome
atrophic -X- _ I-Outcome
or -X- _ I-Outcome
damaged -X- _ I-Outcome
retinal -X- _ I-Outcome
tissue -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
prolonged -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
neurotrophic -X- _ I-Outcome
factors -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
drug -X- _ I-Outcome
delivery -X- _ I-Outcome
, -X- _ I-Outcome
immunomodulation -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
the -X- _ I-Outcome
replacement -X- _ I-Outcome
of -X- _ I-Outcome
mutant -X- _ I-Outcome
genes -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
immunomodulation -X- _ I-Outcome
through -X- _ I-Outcome
viral -X- _ I-Outcome
vector -X- _ I-Outcome
delivery. -X- _ I-Outcome
This -X- _ O
review -X- _ O
will -X- _ O
update -X- _ O
the -X- _ O
reader -X- _ O
on -X- _ O
aspects -X- _ O
of -X- _ O
stem -X- _ B-Intervention
cell -X- _ I-Intervention
and -X- _ I-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
in -X- _ O
diabetic -X- _ O
retinopathy -X- _ O
, -X- _ O
age-related -X- _ O
macular -X- _ O
degeneration -X- _ O
, -X- _ O
retinitis -X- _ O
pigmentosa -X- _ O
and -X- _ O
other -X- _ O
less -X- _ O
common -X- _ O
inherited -X- _ O
retinal -X- _ O
dystrophies. -X- _ O
These -X- _ O
therapies -X- _ O
include -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
adeno-associated -X- _ O
viral -X- _ O
vector-based -X- _ O
therapies -X- _ O
for -X- _ O
treatment -X- _ O
of -X- _ O
various -X- _ O
types -X- _ O
of -X- _ O
retinitis -X- _ O
pigmentosa -X- _ O
and -X- _ O
dry -X- _ O
age-related -X- _ O
macular -X- _ O
degeneration. -X- _ O
Other -X- _ O
potential -X- _ O
therapies -X- _ O
reviewed -X- _ O
include -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
mesenchymal -X- _ O
stem -X- _ O
cells -X- _ O
in -X- _ O
local -X- _ O
immunomodulation -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
stem -X- _ O
cells -X- _ O
in -X- _ O
generating -X- _ O
structures -X- _ O
like -X- _ O
three-dimensional -X- _ O
retinal -X- _ O
sheets -X- _ O
for -X- _ O
transplantation -X- _ O
into -X- _ O
degenerative -X- _ O
retinas. -X- _ O
Finally -X- _ O
, -X- _ O
aspects -X- _ O
of -X- _ O
stem -X- _ B-Intervention
cell -X- _ I-Intervention
and -X- _ I-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
in -X- _ O
diabetic -X- _ O
retinopathy -X- _ O
, -X- _ O
age-related -X- _ O
macular -X- _ O
degeneration -X- _ O
, -X- _ O
retinitis -X- _ O
pigmentosa -X- _ O
, -X- _ O
and -X- _ O
other -X- _ O
less -X- _ O
common -X- _ O
inherited -X- _ O
retinal -X- _ O
dystrophies -X- _ O
will -X- _ O
be -X- _ O
reviewed -X- _ O
. -X- _ O

